CASI Pharma (CASI) Reports ENMD-2076 Phase 2 Met Stage 1 Endpoint in FLC
Tweet Send to a Friend
CASI Pharmaceuticals, Inc. (Nasdaq: CASI) announced that its Phase 2 trial of ENMD-2076 in fibrolamellar carcinoma (FLC) has met its ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
